FAM114A2: A Potential Drug Target and Biomarker for Family with Sequence Similarity 114 Member A2

Target Name: FAM114A2

NCBI ID: G10827

FAM114A2

FAM114A2: A Potential Drug Target and Biomarker for Family with Sequence Similarity 114 Member A2

Introduction

FAM114A2 is a gene located in the X chromosome that has been identified as a potential drug target and biomarker for a family with sequence similarity 114 member A2 (FSSA). FSSA is a rare genetic condition that has been associated with a range of physiological and developmental abnormalities. Although several potential drug targets have been identified for FSSA, little is known about the specific mechanisms underlying the disease. The discovery of FAM114A2 as a potential drug target and biomarker for FSSA provides new insights into the pathophysiology of the disease and highlights its potential as a therapeutic target.

Sequence Similarity 114 and the Importance of Analysis

Sequence similarity 114 (SS114) is a genetic condition that has been identified in several families. It is characterized by the presence of a specific missense mutation, which results in the substitution of a thymine (T) for a guanine (G) at position 114 on the X chromosome. The wild-type gene for SS114 is GSTM114, and the mutant gene is GSTM115.

The discovery of sequence similarity 114 has significant implications for the understanding of the genetic basis of disease. With the increasing power of genetic analysis, researchers have been able to identify families that are homozygous for a specific mutation. In the case of SS114, researchers have identified several families that are homozygous for the GSTM114 mutation. These families are at increased risk for developing SS114 and other related conditions.

The Potential Role of FAM114A2 as a Drug Target

FAM114A2 has been identified as a potential drug target for SS114 due to its unique genetic and molecular characteristics. FAM114A2 is a gene that is expressed in all tissues of the body, including the brain, and is highly conserved across species. It is also localized to the X chromosome, which is known to play a critical role in the development and progression of many diseases.

The identification of FAM114A2 as a potential drug target for SS114 is based on several key findings. Firstly, FAM114A2 has been shown to be involved in the development and progression of several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Secondly, FAM114A2 has has been shown to be a target for several drugs, including inhibitors of the DNA replication complex, which is a key component of the immune system.

FAM114A2 is also known for its role in the development of certain types of cancer, such as leukemia and melanoma. It has been shown to be involved in the regulation of cell growth, apoptosis (programmed cell death), and angiogenesis (the formation of new blood vessels). These processes are critical for the development and progression of cancer, and targeting FAM114A2 may be an effective way to treat these diseases.

The Potential Role of FAM114A2 as a Biomarker

FAM114A2 has also been identified as a potential biomarker for SS114. The GSTM114 gene has been shown to be significantly mutated in many families that are homozygous for SS114. and assessment of SS114.

FAM114A2 may also be a useful biomarker for monitoring the effectiveness of

Protein Name: Family With Sequence Similarity 114 Member A2

The "FAM114A2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FAM114A2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets